Mandate

Vinge advises in the acquisition of Veidekke’s property development operation in Norway and Sweden

Vinge has advised a consortium comprising Fredensborg AS, Fredensborg Bolig AS, Norwegian Property ASA and Union Real Estate Fund III Holding AS in its acquisition of Veidekke’s property development operation in Norway and Sweden

Veidekke has signed an agreement with a consortium comprising Fredensborg AS, Fredensborg Bolig AS, Norwegian Property ASA and Union Real Estate Fund III Holding AS concerning the consortium’s acquisition of Veidekke’s property development operation in Norway and Sweden against a payment of NOK 7.7 billion on a debt-free basis. Closing of the transaction is expected to take place in September 2020.

Vinge’s team consisted of, among others, Assur Badur, Frida Ställborn, Karolina Cohrs and Olof Löfvenberg (Real Property and Environment), Johan Winnerblad, Linda Sengul and Vilhelm Rondahl (M&A), Albert Wållgren, Ludvig Wettergren and Viktor Lennartsson (Financing), Lisa Hörnqvist (Commerical Agreements and IT), Ebba Svenburg (Employment) and the VDR-assistants Jessica Öijer and Carl Bruneheim.

Advokatfirmaet Thommessen has been the consortium’s lead legal counsel in the transaction.

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025